| Name | Title | Contact Details |
|---|
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
NeuroVasc Technologies is a developer of mechanical thrombectomy solutions for revascularization of the brain.
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, the company is headquartered in the United States and has additional offices in Germany, and Poland.
Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.